SCHEMBL3736024

SCHEMBL3736024

COc1ccccc1[C@@H]1CNC[C@H]1C(=O)N1CCOC[C@@H]1c1ccccc1

nearest known ligand 0.74

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ BACE1 P56817 6/20 0.74
▸ TSHR P16473 1/20 0.37
▸ ATM Q13315 1/20 0.37
▸ MEN1 O00255 2/20 0.36
▸ KMT2A Q03164 2/20 0.36
▸ SCD5 Q86SK9 1/20 0.35
▸ CFB P00751 1/20 0.35
▸ MAPK1 P28482 1/20 0.35
▸ TMEM97 Q5BJF2 1/20 0.35
▸ SIGMAR1 Q99720 1/20 0.35
▸ HTR2A P28223 1/20 0.35
▸ HTR2C P28335 1/20 0.35
▸ HTR2B P41595 1/20 0.35
▸ TRPV1 Q8NER1 1/20 0.34
▸ MC4R P32245 1/20 0.34
▸ KCNH2 Q12809 1/20 0.34
▸ AKR1C3 P42330 1/20 0.34
▸ ROCK2 O75116 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13041188 0.85 BACE1 (0.53) BACE1TSHRATMMEN1KMT2A
SCHEMBL3739919 0.85 BACE1 (1.00) BACE1SCD5MAPK1TMEM97SIGMAR1
SCHEMBL3744413 0.85 BACE1 (1.00) BACE1SCD5MAPK1TMEM97SIGMAR1
SCHEMBL3741323 0.85 BACE1 (1.00) BACE1SCD5MAPK1TMEM97SIGMAR1
SCHEMBL3736070 0.84 BACE1 (0.81) BACE1SCD5MAPK1TMEM97SIGMAR1
SCHEMBL3736938 0.83 BACE1 (0.79) BACE1SCD5MAPK1HTR2CMC4R
SCHEMBL3734320 0.83 BACE1 (0.71) BACE1TSHRATMSCD5MAPK1
SCHEMBL3734323 0.83 BACE1 (0.71) BACE1TSHRATMSCD5MAPK1
SCHEMBL3734319 0.83 BACE1 (0.71) BACE1TSHRATMSCD5MAPK1
SCHEMBL3734255 0.83 BACE1 (0.71) BACE1TSHRATMSCD5MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2231558-B1 3,4-SUBSTITUTED PYRROLIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE MERCK SHARP & DOHME (US) 2014-09-03 — — EP claimed
US-8354545-B2 3,4-substituted pyrrolidine beta-secretase inhibitors for the treatment of alzheimer's disease Merck, Sharp & Dohme, Corp. (US) 2013-01-15 — — US claimed
EP-2231558-A1 3,4-SUBSTITUTED PYRROLIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE Merck Sharp & Dohme Corp. (US) 2010-09-29 — — EP claimed
WO-2009078932-A1 3,4-SUBSTITUTED PYRROLIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE MERCK & CO., INC. (US) 2009-06-25 — — WO claimed
EP-2231558-B1 3,4-SUBSTITUTED PYRROLIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE MERCK SHARP & DOHME (US) 2014-09-03 — — EP disclosed
US-8354545-B2 3,4-substituted pyrrolidine beta-secretase inhibitors for the treatment of alzheimer's disease Merck, Sharp & Dohme, Corp. (US) 2013-01-15 — — US disclosed
US-20100280009-A1 3,4-SUBSTITUTED PYRROLIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE MERCK SHARP & DOHME LLC 2010-11-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100280009-A1 3,4-SUBSTITUTED PYRROLIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE BACE1, BACE2, PSEN1 BACE1 1/4885TSHR 4817/4885ATM 3677/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback